Insight Advisors LLC PA Has $541,000 Holdings in Pfizer Inc. (NYSE:PFE)

Insight Advisors LLC PA cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 26.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 12,301 shares of the biopharmaceutical company’s stock after selling 4,460 shares during the quarter. Insight Advisors LLC PA’s holdings in Pfizer were worth $541,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of PFE. TD Capital Management LLC lifted its stake in shares of Pfizer by 12.0% during the 2nd quarter. TD Capital Management LLC now owns 2,183 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 234 shares in the last quarter. Highland Private Wealth Management lifted its stake in shares of Pfizer by 2.8% during the 2nd quarter. Highland Private Wealth Management now owns 8,698 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 238 shares in the last quarter. HawsGoodwin Investment Management LLC lifted its stake in shares of Pfizer by 0.8% during the 2nd quarter. HawsGoodwin Investment Management LLC now owns 30,141 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 239 shares in the last quarter. TAP Consulting LLC lifted its stake in shares of Pfizer by 1.2% during the 2nd quarter. TAP Consulting LLC now owns 20,633 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 246 shares in the last quarter. Finally, Mirador Capital Partners LP lifted its stake in shares of Pfizer by 1.1% during the 2nd quarter. Mirador Capital Partners LP now owns 22,092 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 247 shares in the last quarter. Hedge funds and other institutional investors own 64.93% of the company’s stock.

A number of analysts recently commented on the stock. SVB Leerink upped their price target on shares of Pfizer from $49.00 to $50.00 and gave the company a “market perform” rating in a research note on Monday, September 20th. Mizuho upped their target price on shares of Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Friday, July 30th. Morgan Stanley upped their target price on shares of Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Berenberg Bank reaffirmed a “neutral” rating and set a $43.00 target price on shares of Pfizer in a report on Tuesday, June 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a report on Monday, September 13th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $42.85.

Shares of NYSE:PFE opened at $43.94 on Friday. The company’s fifty day moving average price is $45.45 and its 200-day moving average price is $40.83. The firm has a market capitalization of $246.36 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a one year low of $33.36 and a one year high of $51.86. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.10. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. The firm had revenue of $18.98 billion for the quarter, compared to analyst estimates of $17.54 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 4.12 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 3.55%. The ex-dividend date is Thursday, November 4th. Pfizer’s dividend payout ratio is currently 70.27%.

In related news, SVP Jennifer B. Damico sold 1,661 shares of the stock in a transaction on Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction on Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at approximately $489,889.80. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Story: Trade War

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.